Stock On Watch: Could La Jolla Pharmaceutical Company Crash Even More? The Stock Had Another Big Decline Today

Stock On Watch: Could La Jolla Pharmaceutical Company Crash Even More? The Stock Had Another Big Decline Today

The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a huge mover today! About 99,979 shares traded hands. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 15.45% since March 9, 2016 and is uptrending. It has outperformed by 8.04% the S&P500.
The move comes after 8 months negative chart setup for the $365.87M company. It was reported on Oct, 12 by Barchart.com. We have $18.28 PT which if reached, will make NASDAQ:LJPC worth $43.90M less.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on November, 4. They expect $-1.00 EPS, down 42.86% or $0.30 from last year’s $-0.7 per share. After $-0.90 actual EPS reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Out of 3 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. La Jolla Pharmaceutical Company has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Tuesday, September 8 by Chardan Capital Markets. Cowen & Co initiated the shares of LJPC in a report on Tuesday, February 9 with “Outperform” rating. Lake Street initiated La Jolla Pharmaceutical Company (NASDAQ:LJPC) rating on Tuesday, May 24. Lake Street has “Buy” rating and $25 price target. The firm has “Hold” rating given on Tuesday, August 11 by Zacks.

According to Zacks Investment Research, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.”

Insitutional Activity: The institutional sentiment increased to 1.9 in Q2 2016. Its up 0.56, from 1.34 in 2016Q1. The ratio improved, as 6 funds sold all La Jolla Pharmaceutical Company shares owned while 14 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 15.94 million shares or 0.70% less from 16.05 million shares in 2016Q1.
The New York-based Perceptive Advisors Ltd Liability has invested 1.48% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Great West Life Assurance Com Can last reported 2,654 shares in the company. Sabby Management Limited Liability Corp, a New Jersey-based fund reported 206,131 shares. Franklin Resources has 0.01% invested in the company for 965,600 shares. Hollencrest Securities Llc owns 22,092 shares or 0.05% of their US portfolio. Natl Planning owns 17,525 shares or 0.02% of their US portfolio. Blackrock Investment Mngmt Limited Liability Co has invested 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Landscape Lc has 53,254 shares for 0.11% of their US portfolio. Janus Mgmt Limited Liability Com last reported 1.24 million shares in the company. Morgan Stanley last reported 0% of its portfolio in the stock. Granahan Inv Mgmt Ma holds 0.12% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 214,229 shares. Gsa Cap Limited Liability Partnership, a United Kingdom-based fund reported 44,900 shares. The Texas-based Wfg Advisors Lp has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Vanguard Grp Inc last reported 0% of its portfolio in the stock. Wells Fargo Co Mn last reported 18,160 shares in the company.

Insider Transactions: Since September 9, 2016, the stock had 1 insider buy, and 0 sales for $2.76 million net activity. Another trade for 139,035 shares valued at $2.76M was bought by TANG KEVIN C.

More notable recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Businesswire.com which released: “La Jolla Pharmaceutical Company Announces Agreement with European Medicines …” on September 07, 2016, also Businesswire.com with their article: “La Jolla Pharmaceutical Company Announces Financial Results for the Three and …” published on August 08, 2016, Businesswire.com published: “La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of …” on September 09, 2015. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) were released by: Businesswire.com and their article: “La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent …” published on November 30, 2015 as well as Businesswire.com‘s news article titled: “La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results …” with publication date: May 06, 2016.

LJPC Company Profile

La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. The Company’s product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment